DrugPatentWatch Database Preview

Drugs in Development Information for N,N-Dimethyltryptamine

« Back to Dashboard

What is the development status for investigational drug N,N-Dimethyltryptamine?

N,N-Dimethyltryptamine is an investigational drug.

There have been 6 clinical trials for N,N-Dimethyltryptamine. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1^st 2020.

The most common disease conditions in clinical trials are Depression, Alcoholism, and Alcohol Drinking. The leading clinical trial sponsors are Heffter Research Institute, Johns Hopkins University, and Beckley Foundation.

There are one hundred and fifty US patents protecting this investigational drug and eight hundred and seventy-five international patents.

Summary for N,N-Dimethyltryptamine

US Patents	150
International Patents	875
US Patent Applications	412
WIPO Patent Applications	199
Japanese Patent Applications	58
Clinical Trial Progress	Phase 1 (2020-12-01)
Vendors	27

Recent Clinical Trials for N,N-Dimethyltryptamine

Title	Sponsor	Phase
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder	Johns Hopkins University	Phase 2
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors	Heffter Research Institute	Phase 1
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors	River Styx Foundation	Phase 1

See all N,N-Dimethyltryptamine clinical trials

Clinical Trial Summary for N,N-Dimethyltryptamine

Top disease conditions for N,N-Dimethyltryptamine

Top clinical trial sponsors for N,N-Dimethyltryptamine

See all N,N-Dimethyltryptamine clinical trials

US Patents for N,N-Dimethyltryptamine

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
N,N-Dimethyltryptamine		Methods of improving behavioral therapies	Emory University (Atlanta, GA)
N,N-Dimethyltryptamine		Complex and structurally diverse compounds	The Board of Trustees of the University of Illinois (Urbana, IL)
N,N-Dimethyltryptamine		Factor XIa inhibitors	Merck Sharp & Dohme Corp. (Rahway, NJ)
N,N-Dimethyltryptamine		Pharmaceutical compositions resistant to abuse	EGALET LTD. (London, GB)
N,N-Dimethyltryptamine		Formulations of histone deacetylase inhibitor and uses thereof	Pharmacyclics LLC (Sunnyvale, CA)
N,N-Dimethyltryptamine		Methods, devices and systems for pulmonary delivery of active agents	Syqe Medical Ltd. (Tel-Aviv, IL)
N,N-Dimethyltryptamine		Abuse-deterrent controlled release formulations	Patheon Softgels Inc. (High Point, NC)

International Patents for N,N-Dimethyltryptamine

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
N,N-Dimethyltryptamine	World Intellectual Property Organization (WIPO)	WO2013142873	2032-03-23
N,N-Dimethyltryptamine	European Patent Office	EP3134408	2034-04-22
N,N-Dimethyltryptamine	World Intellectual Property Organization (WIPO)	WO2015164308	2034-04-22
N,N-Dimethyltryptamine	Australia	AU2010211376	2029-02-06
N,N-Dimethyltryptamine	Australia	AU2013257533	2029-02-06
N,N-Dimethyltryptamine	Canada	CA2751627	2029-02-06
N,N-Dimethyltryptamine	Denmark	DK2393487	2029-02-06